SCHEMBL23525876

SCHEMBL23525876

COc1cc2c(C(F)(F)F)n[nH]c(=O)c2cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 7/20 0.46
PDE3B Q13370 6/20 0.46
PDE4A P27815 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ENPP1 P22413 5/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAOA P21397 1/20 0.39
MITF O75030 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4134456 0.80 PIK3CA (0.47) PDE4BKDM4EALDH1A1HPGDENPP1
SCHEMBL11546262 0.76 PDE4A (0.49) PDE3APDE3BPDE4APDE4BPDE4C
SCHEMBL25547523 0.74 ENPP1 (0.42) PDE3APDE3BPDE4APDE4BPDE4C
SCHEMBL25141598 0.72 PRMT5 (0.40) ALDH1A1SMN1; SMN2AR
SCHEMBL11552287 0.72 PDE3A (0.46) PDE3APDE3BPDE4APDE4BPDE4C
SCHEMBL22598477 0.71 PDE3B (0.39) PDE3APDE3BPDE4APDE4BPDE4C
SCHEMBL14915843 0.71 PRKAG1 (0.46) PDE3APDE3BPDE4APDE4BPDE4C
SCHEMBL29426552 0.71 PRMT5 (0.43) ALDH1A1SMN1; SMN2AR
SCHEMBL23526315 0.71 PRMT5 (0.46) ALDH1A1AR
SCHEMBL29426626 0.71 PRMT5 (0.46) ALDH1A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
CN-119462626-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2025-02-18 CN disclosed
CN-115135315-B SOS1 inhibitors 米拉蒂治疗股份有限公司 2024-11-26 CN disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 US disclosed
CN-115135315-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2022-09-30 CN disclosed
US-20210188857-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2021-06-24 US disclosed
US-20210188857-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 PDE3A 3274/4885PDE3B 3268/4885PDE4A 3403/4885
US-20230137886-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 PDE3A 3274/4885PDE3B 3268/4885PDE4A 3403/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 PDE3A 3274/4885PDE3B 3268/4885PDE4A 3403/4885
US-20210188857-A1 SOS1 INHIBITORS SOS1, SOS2, SOST PDE3A 2559/4885PDE3B 2527/4885PDE4A 2453/4885
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST PDE3A 2559/4885PDE3B 2527/4885PDE4A 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.